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Bullous pemphigoid is a blistering skin disease char-
acterized by autoantibodies directed against the
NC16A domain of bullous pemphigoid 180 (collagen
XVII), a transmembrane protein of epidermal basal
cells. Passive transfer studies in mice have shown
that antibodies that bind to this immunodominant
region of bullous pemphigoid 180 are capable of
inducing a skin disease that closely mimics bullous
pemphigoid, supporting the hypothesis that epitopes
within NC16A are involved in the pathogenesis of
bullous pemphigoid. In this study, we examined the
autoimmune T cell response in bullous pemphigoid
patients. T cells from eight of 12 bullous pemphigoid
patients, all of whom had circulating anti-bullous
pemphigoid 180 autoantibodies, showed a speci®c
proliferative response to recombinant forms of
NC16A. T cell lines and clones developed from four
of these patients recognize the same NC16A peptides
as those targeted by autoantibodies from the corre-
sponding individuals. These NC16A-responding T
lymphocytes express a/b T cell receptors and CD4
memory T cell surface markers and exhibited a Th1/
Th2 mixed cytokine pro®le that may support the
production of antibodies. This new information will
aid in de®ning the key steps involved in the develop-
ment of the autoimmune response in bullous pem-
phigoid. Key words: autoimmunity/basement membrane
zone/collagen/hemidesmosome/skin. J Invest Dermatol
115:955±961, 2000
B
ullous pemphigoid (BP) is a cutaneous autoimmune
disorder ®rst described by Lever in 1953 (Lever,
1953). This disease, which mainly occurs in elderly
patients without gender bias (Lin et al, 1998), is
characterized by subepidermal blistering and deposi-
tion of IgG and complement in the basement membrane zone
(BMZ) of the skin (Jordon et al, 1967; Provost and Tomasi,
1973). Two hemidesmosomal antigens are recognized by the
great majority of BP sera, one associated with the intracellular
plaque, BP230 (BPAg1) (Mueller et al, 1989) and the other the
transmembrane glycoprotein known as BP180 (BPAg2 or
collagen XVII) (Labib et al, 1986; Diaz et al, 1990; Giudice
et al, 1992). Immunodominant epitopes, including one desig-
nated MCW-1, recognized by BP autoantibodies are located
within the NC16A domain of the BP180 antigen (Giudice et al,
1993; Zillikens et al, 1997).
The major clinical, histologic, and immunologic features of BP
are also exhibited by patients with herpes gestationis (HG), a
pregnancy-associated nonherpetic blistering disease (Provost and
Tomasi, 1973; Shornick et al, 1983). Over 95% of HG sera
recognize the MCW-1 epitope of the BP180 ectodomain (Lin et al,
1999a). There are, however, some interesting differences, e.g., the
majority of BP autoantibodies belong to the IgG4 subclass (Suzuki
et al, 1994), whereas in HG, IgG1 is the predominant autoantibody
isotype (Kelly et al, 1989). Furthermore, immunogenetic studies
have shown that BP is associated with the HLA-DQB1*0301 allele
(Delgado et al, 1996), whereas HG is linked to HLA-DRB1*0401/
x or DRB1*0301 MHC II alleles (Shornick et al, 1995).
Several lines of evidence support the hypothesis that an
autoimmune response against BP180 is a key step in the
initiation and evolution of BP. For example, our research group
has developed and characterized a passive transfer model of BP,
in which neonatal BALB/C mice are injected with antibodies
that recognize a segment of the murine BP180 protein that is
homologous with the human NC16A domain (Liu et al, 1993,
1995a). The antibody-treated animals consistently develop
subepidermal blisters that duplicate the features of the human
disease, such as complement ®xation at the BMZ (Liu et al,
1995b) and neutrophil recruitment (Liu et al, 1997). These
®ndings support the idea that BP autoantibodies against the
BP180 antigen are directly involved in the initiation of the
subepidermal blistering in BP patients and, more speci®cally,
implicate the NC16A domain in the initiation of the BP
autoimmune response.
The humoral autoimmune response in BP and HG and the
epidermal antigens recognized by BP autoantibodies have been
the focus of numerous studies carried out over the past 25 y.
Very little, however, is known about the immunoregulatory
cellular mechanisms involved in the pathogenesis of BP or HG.
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Recently, it was demonstrated that T cells from normal
individuals or BP patients expressing the HLA-DQB1*0301
allele respond to recombinant proteins encompassing the entire
extracellular domain of BP180, providing the ®rst evidence that
T lymphocytes participate in the autoimmune response in this
disease (BuÈdinger et al, 1998). As it was shown that the NC16A
domain of the BP180 bear autoantibody epitopes that may be
involved in the pathogenesis of BP, in this study, we
concentrated our effort in characterizing the T cell autoimmune
response in BP patients and de®ning the responsive T cell
epitopes within the NC16A domain. Here, we demonstrate
unequivocally that the NC16A region of BP180 harbors
epitopes recognized by both T cells and autoantibodies from
BP patients. Furthermore, BP180-speci®c T cell lines and clones
generated from BP patients express the CD4+ memory T cell
phenotype and secrete Th1/Th2 mixed cytokines.
MATERIALS AND METHODS
BP patients and controls Sera and peripheral blood were obtained
from 12 BP patients. All samples were collected from patients when their
diseases are in an active stage. Clinically, these patients showed linear IgG
and C3 deposits in the BMZ of lesional skin. Indirect immuno¯uorescence
staining (Table I) was performed using human foreskin as substrate to
detect anti-BMZ IgG (Jordon et al, 1976; Katz et al, 1976). Patients with
Table I. The MHC class II phenotype and autoimmune response of BP patients
Patients MHC II alleles Autoantibody responsesa







Sex Age Indirect immuno-
¯uorescence titer
EDc 1402/0802 0301/0402 ± + + 3.7 M 74 1:80
KL 1501/1501 ND + + + 3.4 M 79 1:40
SC 1301/1501 0602/0603 + + + 3.5 M 30 ±
BM 0701/1302 0201/0604 + + + 7.8 M 65 1:40
LT 1601/1201 0502/0301 ± + + 6.2 F 68 1:160
IK 0102/1101 0301/0501 ± + + 6.1 F 79 ±
HP 0401/1101 0301/0302 ± + + 9.5 M 67 ±
AN 04011/0101 0501/0301 + + + 3.4 F 81 1:40
ES 0701/1101 0502/0301 + ± ± ± F 82 1:20
AP 1201/1301 0301/0501 + ± ± ± M 79 1:20
LH 0804/1503 0301/0602 + ± ± ± M 69 1:40
NE 0701/1101 0201/0304 + ± ± ± F 65 1:320
a Epidermal antigens used in the immunoblotting assays were extracted from human foreskin. ND, not done.
b The proliferation of BP T cells to NC16A1±5 was performed as described in the Materials and Methods. The results were shown as SI. SI > 3.0 was considered a
positive response. SI < 3.0 was marked as ±.
c Patient ED deceased at age of 74.
Figure 1. Recombinant BP180 GST fusion proteins encompassing the NC16A region. BP180 contains a single transmembrane domain (``TM'').
The cytoplasmic region is shown to the left and the carboxy-terminal ectodomain, consisting of 15 interrupted collagen domains, is shown to the right. The
NC16A region has been arbitrarily divided into ®ve subregions, each of approximately 15 amino acids in length. Every BP180 fusion protein shown in this
diagram possesses an N-terminal GST tail, and the dotted lines represent deleted peptide stretches. The immunoblotting results of BP sera included in this
study are shown in the table to the right. ``+'' and ``±'' indicate positive and negative immunoblotting results, respectively.
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other cutaneous autoimmune diseases, such as pemphigus vulgaris (n = 11),
pemphigus foliaceus (n = 4), systemic lupus erythematosus (SLE) (n = 2),
epidermolysis bullosa acquisita (n = 1), and psoriasis (n = 2), were included
along with normal volunteers (n = 7) as controls. Other information about
the BP patients recruited in this study, including age, sex, indirect IF serum
titers, and the expression of HLA-DRB1 and -DQB1 alleles, are presented
in Table I.
Epstein±Barr virus-transformed B cell lines and antibodies Epstein±
Barr virus-transformed B cell lines from BP patients were developed as
previously described (Ohlin et al, 1989). These cell lines were cultured in
RPMI 1640 medium containing 10% fetal bovine serum (Hyclone, Salt Lake
City, UT) and were used as antigen-presenting cells in the maintenance of T
cell clones and in T cell proliferation assays.
Anti-CD3, -CD4, -CD8, CD19, -HLA-DR (clone B-F1), -CD45RA,
and ¯uorescein-labeled goat F(ab¢)2 anti-mouse immunoglobulin were
purchased from Biosource International (Camarillo, CA). Anti-HLA-DQ
and anti-HLA-DP and anti-T cell receptor-a/b antibodies were obtained
from Becton-Dickinson (San Jose, CA). Anti-CD45RO was purchased
from Immunotech (Westbrook, ME). Murine IgG2a and IgG1 were
used as negative controls and were obtained from DAKO (Carpinteria,
CA).
Preparationof recombinantBP180 fusionproteins and sec180e The
following segments of the human BP180 antigen were expressed in Escherichia
coli as glutathione S-transferase (GST) fusion proteins: NC16A1±5 (aa 490±
562) (Giudice et al, 1993); NC16A2±5 (aa 507±562); NC16A2±4 (aa 507±
548); NC16A1±3 (aa 490±534); NC16A2±3 (aa 507±534); NC16A1 (aa
490±506); NC16A3 (aa 521±534); NC16A2.5 (aa 514±532); and NC16A2
(aa 507±522) (see Fig 1; Giudice et al, 1993; Zillikens et al, 1997). To generate
the above BP180 segments, the BP180 cDNAs encoding the respective
regions were ampli®ed by polymerase chain reaction (PCR) and subcloned
into the bacterial expression vector pGEX2T (Pharmacia, Piscataway, NJ) as
described (Liu et al, 1995a). These BP180-GST fusion proteins were
expressed in E. coli strain DH5a and puri®ed by glutathione agarose af®nity
chromatography (Liu et al, 1992). The puri®ed fusion proteins were dialyzed
against phosphate-buffered saline, concentrated by ultra®ltration and ®lter-
sterilized. The protein concentration was determined by the Bradford
protein assay (Bio-Rad, Hercules, CA). Sec180e, a recombinant protein
encompassing the entire extracellular domain of BP180 was constructed and
expressed in a mammalian expression system as described (Balding et al, 1997).
Other unrelated antigens, such as recombinant GST and fragments of
desmoglein-1 (Dsg1-K; aa 424±510) and desmoglein-3 [Dsg3-A (aa 145±
192), -B (aa 240±303), and -C (aa 570±614)] (Lin et al, 1997b), were used as
controls in this study.
Immunoblotting assays Sodium dodecyl sulfate±polyacrylamide gel
electrophoresis was performed as described (Zillikens et al, 1997). Brie¯y,
sec180e, human foreskin epidermal extracts, and NC16A fusion proteins
were fractionated by sodium dodecyl sulfate±polyacrylamide gel electro-
phoresis and transferred on to nitrocellulose (Gibco BRL, Gaithersburg,
MD). Blots were blocked with PTX buffer (0.01 M phosphate, pH 7.5,
0.2% Triton X-100, 0.15 M NaCl, 1 mM ethylenglycol-bis-(b-amino-
ethylether)-N,N,N ¢,N ¢-tetraacetic acid, 4% bovine serum albumin) for
45 min. Sera from BP patients and controls were diluted in PTX buffer at
1:100 or 1:50 and incubated with the blots overnight at 4°C. The blots
were then washed, blocked for 30 min with PTX buffer, and incubated for
2 h with 125I-labeled Staphylococcus aureus protein A (Sigma, St Louis, MO)
at a concentration of 105 cpm per ml. The immunoreactive bands were
visualized by autoradiography.
Liquid phase immunoadsorption Immunoadsorption procedures
were conducted as described previously (Zillikens et al, 1997). The sera
were diluted in PTX and incubated overnight with recombinant GST or
with GST fusion proteins containing segments of the BP180 NC16A
domain. The mixtures were then centrifuged at 10,000 3 g for 15 min at
4°C. The preadsorbed sera were subsequently used in the immunoblotting
assays against various NC16A fusion proteins and sec180e.
Major histocompatibility complex (MHC) class II analysis The
analysis of HLA-DRB1 and DQB1 of BP patients was carried out using the
sequence-speci®c oligonucleotide hybridization technique of PCR
ampli®ed DNA (Fernandez-Vina et al, 1994; Moraes et al, 1997). The
results are shown in Table I.
Puri®cation of peripheral blood mononuclear cells (PBMC) and
isolation of T lymphocytes PBMC were isolated by Ficoll-Hypaque
(Pharmacia) density gradient separation (Lin et al, 1997a). T cells were
subsequently puri®ed by E-rosetting using 2-amino-ethylisothiouronium
bromide (Sigma)-treated sheep red blood cells (Colorado Serum, Denver,
CO) (Indiveri et al, 1980). The puri®ed T cells were washed with medium
three times, and resuspended in RPMI 1640 medium supplemented with
10% human AB serum (NABI, Miami, FL) for the T cell proliferation
assays. In some experiments, CD4- or CD8-positive T cells were depleted
from puri®ed T cells using speci®c antibodies and a magnetic cell sorter
(Miltenyi et al, 1989). The CD4- or CD8-depleted T cells were used in the
proliferation assays as described below.
T cell proliferation assays T cell responses to BP180 fusion proteins
were determined by proliferation assays as described (Lin et al, 1997a).
Brie¯y, T cells at a density of 105 per ml were cultured with 105 per ml of
irradiated autologous PBMC as antigen-presenting cells along with fusion
proteins in wells of 96-well U-bottom plates for 7 d. Phytohemagglutinin
(Sigma) at 0.25 mg per ml or interleukin (IL) ±2 at 10 U per ml
(Collaborative Research, Bedford, MA) served as positive controls in T
cell proliferation experiments. The GST, GST-Dsg1, and GST-Dsg3
fusion proteins were included in these experiments as negative controls.
Cells in individual wells were pulsed with 1 mCi of 3H-thymidine (ICN,
Costa Mesa, CA) during the last 18 h of incubation and then harvested
using an automated cell harvester (Inotech Biosystems, Lansing, MI). The
proliferation of T cells was determined by measuring the 3H-thymidine
uptake by liquid scintillation counting. Data were presented as average
cpm 6 SD or stimulation index (SI) (average cpm of cells treated with
fusion proteins 4 average cpm of cells treated with GST at the same
concentration). An SI equal to or greater than 3 was considered a positive
response.
Development and characterization of BP180-speci®c T cell lines
and clones The NC16A-speci®c T cell lines and clones were developed
from four BP patients using NC16A fusion protein (aa 490±560) following
the in vitro repeat stimulation protocol as described previously (Lin et al,
1997a). The cell surface expression of CD3, CD4, CD8, CD19, CD45RA,
CD45RO, and T cell receptor-a/b on BP180-speci®c T cells was
examined by ¯ow cytometric analysis using a FACScan ¯ow cytometer
(Becton Dickinson) and speci®c monoclonal antibodies. Mouse IgG was
used as a negative control. Fluorescein-conjugated F(ab¢)2 anti-mouse
immunoglobulin was used as the secondary antibody.
The antigen speci®city of derived T cell lines and clones was examined
by culturing 5 3 104 per ml T cells with 5 3 104 per ml of irradiated
autologous PBMC or Epstein±Barr virus-transformed B cells pulsed with
20 mg per ml of antigen for 5 d at 37°C in 96 well plates (Fisher Scienti®c,
Pittsburgh, PA) at a ®nal volume of 200 ml. T cells in each well were pulsed
with 1 mCi of 3H-thymidine during the last 18 h of incubation. An SI equal
to or greater than 3 was considered a positive response. Phyto-
hemagglutinin at 0.25 mg per ml or IL-2 (Biosource) at 10 U per ml were
used as positive controls in these proliferation assays.
Cytokine pro®le analysis of NC16A-speci®c T cells T cells from
patients and controls were cultured in a 24-well plate (106 cells per well) in
the presence of 10 ng per ml of phorbol myristate acetate (Sigma) and
100 ng per ml of anti-CD3 antibodies (Del Prete et al, 1995). Stimulated
cells were collected and washed before total RNA was extracted by Trisol
reagent (Gibco BRL). The ®rst-strand cDNA was synthesized using
Superscript (Gibco BRL) following the protocol provided by the
manufacturer. The mRNA of cytokines expressed by NC16A-speci®c T
lymphocytes were PCR-ampli®ed using speci®c primer sets (Brenner et al,
1989) and Taq polymerase (Gibco BRL). The PCR products were
separated on a 1.5% agarose gel and visualized by ethidium bromide
staining. The following are the sequences of the PCR primer sets: b-actin:
5¢-TCCTGTGGCATCCACGAAACT-3¢ and 5¢-GAAGCATTTGCG-
GTGGACGAT-3¢; IL-2: 5¢-AACTCCTGTCTTGCATTGCA-3¢ and 5¢-
GTGTTGAGATGATGCTTTGAC-3¢; IL-4: 5¢-CAACTTTGCTG-
GACTTCAACA-3¢ and 5¢-TCCAACGTACTCTGGTTGG-3¢; IL-5:
5¢-AGGATGCTTCTGCATTTGAG-3¢ and 5¢-CTATTATCCATC-
TCGGTGTTC-3¢; IL-6: 5¢-AACTCCTTCTCCATAAGCG-3¢ and 5¢-
TGGACTGCAGGAACTCCTT-3¢; transforming growth factor (TGF)
-b: 5¢-AACA-TGATCGTGCGCTCCTGCAAGTGCAGC-3¢ and 5¢-
AAGGAATAGTGCAGACAGGC-AGGA-3¢; and interferon (IFN) -g:
5¢-ATGAAATATACAAGTTATATC-3¢ and 5¢-TTACTGGGATGCT-
CTTCGACCTCGAAACAGCAT-3¢. The expected sizes of PCR
products are as follows: b-actin, 314 bp; IL-2, 441 bp; IL-4, 345 bp; lL-5,
394 bp; IL-6, 610 bp; TGF-b, 200 bp; and IFN-g, 501 bp. Commercial
enzyme-linked immunosorbent assay kits were used to verify the cytokine
pro®les of these BP180-speci®c T cells (Cytimmune Sciences, College
Park, MD).
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RESULTS
Most, but not all, BP patients express autoantibodies
directed against the BP180 extracellular domain Serum
samples from the BP patients were assayed by immunoblotting for
reactivity with antigens from a human epidermal extract and with a
recombinant protein, sec180e, corresponding to the entire BP180
ectodomain. A summary of the results is presented in Table I.
Eight of the 12 BP sera (SC, BM, KL, AN, ED, IK, HP, and LT)
recognized BP180 extracted from human epidermis as well as the
sec180e protein, indicating that these patients were producing
autoantibodies that react with the extracellular domain of BP180.
Four of these BP180-positive sera (SC, BM, KL, AN) and the four
BP180-negative BP sera (LH, ES, AP, and NE) contained
immunoreactivity with the BP230 antigen.
Interestingly, although serum NE (obtained in 1998) reacted
with BP230, but not BP180, a serum sample that had been
obtained from this same patient 6 y earlier (1992) was also tested
and was shown to contain IgG reactivity against human epidermal
BP180 and sec180e, but not BP230, when tested by immunoblot-
ting at a dilution of 1:100 (Fig 2). Epitope mapping analysis using
recombinant BP180 proteins revealed that the serum sample
collected in 1992 recognized NC16A3 (aa 521±534) and
NC16A2.5 (aa 514±532) segments of the NC16A domain.
Similar to the results obtained by serum NE reported in Table I,
two other serum samples from this patient obtained more recently
(in 1998) failed to recognize BP180 (data not shown).
Sec180e positive BP sera recognize NC16A fusion
proteins To de®ne the epitope(s) recognized by the BP sera in
this study, immunoblotting assays were performed using GST-
BP180 fusion proteins as the antigen source (Fig 1). As reported in
Fig 1, all eight of the sec180e-positive BP sera reacted with one or
more sites within the NC16A domain: six sera reacted with the
NC16A2 (aa 507±520) epitope, ®ve with NC16A3 (aa521±534),
®ve with NC16A2.5 (aa 514±532), and two with NC16A1 (aa
490±506). The four BP sera that reacted with BP230, but not
BP180, isolated from human epidermis also failed to react with any
of these BP180 fusion proteins even at a low serum dilution (1:25).
In order to determine whether these BP sera reacted with sites
on the BP180 ectodomain outside of the NC16A domain, the
sec180e-positive BP sera were depleted of reactivity with
NC16A1±3 and subsequently assayed for reactivity with sec180e.
It was clear that after preadsorption against NC16A1±3, all eight BP
sera lost their ability to react with sec180e (not shown). Therefore,
within the limits of the sensitivity of this immunoblotting assay, we
were unable to detect any extracellular BP autoantibody-reactive
epitopes outside the BP180 NC16A domain.
T lymphocytes from BP patients speci®cally respond to
NC16A To examine whether T lymphocytes respond to BP180,
T cells were puri®ed from PBMC of BP patients and analyzed
using a standard T cell proliferation protocol. As reported in
Table I, T cells from the eight BP patients whose sera recognized
sec180e and NC16A proliferated in response to NC16A1±5 (aa
492±560), but showed no response to GST or unrelated epidermal
antigens, such as Dsg-1 and Dsg-3. These ®ndings indicated that
BP T cells speci®cally proliferate in response to BP180.
Furthermore, T cells from other patient groups, such as
pemphigus vulgaris (n = 11), pemphigus foliaceus (n = 4), systemic
lupus erythematosus (n = 2), epidermolysis bullosa acquisita (n = 1),
and psoriasis (n = 2), and normal controls (n = 7) did not respond to
NC16A1±5 (not shown), indicating that the NC16A-induced T
cell proliferation response is speci®c to BP. Interestingly, T cells
isolated from BP patients expressing only anti-BP230
autoantibodies failed to respond to the NC16A fusion protein
(Table I).
NC16A responsive BP T lymphocytes are CD4-positive
cells It is known that CD4 Th cells are capable of promoting
antibody production in B cells in an antigen-dependent response.
As BP is an antibody-mediated autoimmune disease, it is postulated
that the BP180-speci®c T cells are of the CD4 lineage. To examine
further the phenotype of the NC16A-responsive T cells, the T cell
preparations were selectively depleted of CD4+ or CD8+ T cells by
magnetic sorting using anti-CD4 or anti-CD8 antibodies,
respectively, and subsequently examined in the proliferation
assay. As shown in Fig 3(A), T cells from a representative patient
proliferated when incubated with NC16A fusion proteins in a
concentration-dependent manner. These observed T cell responses
were abolished when CD4+ T cells were depleted (Fig 3C), but
not when the CD8+ T cells were depleted (Fig 3B), suggesting that
the NC16A-responsive T cells are of the CD4 T cell lineage.
Antigen speci®city of BP180-speci®c T cells developed from
BP patients To facilitate the characterization of BP-speci®c T
cells, T cell lines were developed from BP patients as described (Lin
et al, 1997a), and T cell clones were subsequently derived from the
cell lines by limiting dilution (Taswell, 1981). The antigen
speci®city of these T cells was determined by proliferation assays
using BP180 fusion proteins as the presenting antigens. As shown in
Fig 4, T cells developed from BP patients speci®cally respond to
NC16A fusion proteins in a concentration-dependent manner.
These BP T cell lines and clones do not proliferate to fusion
proteins derived from unrelated skin antigens, such as Dsg1 and
Dsg3 (not shown), establishing the speci®city of the BP180
response exhibited by these cells. T cell clones (n = 6) from patient
BM, whose serum recognized the NC16A3 peptide, proliferated in
response to NC16A3, but did not exhibit a response to other
fragments of NC16A, such as NC16A2 and NC16A1 (Fig 4A, B).
On the other hand, T cell lines and clones developed from two
other BP patients with antibodies recognizing the NC16A2 site
showed an exclusive proliferation response to the NC16A2 peptide
(aa 507±520) (Fig 4C, D). These results indicate that both
autoimmune T and B cells from a given patient recognize
extracellular BP180 epitopes located in close proximity to one
another (within a 15 amino acid stretch).
Cell surface phenotypes and cytokine pro®les of NC16A-
speci®c T cells Flow cytometric analysis was used to determine
the cell surface phenotype of the BP180-speci®c T cells developed
from BP patients. We found that all cell lines and clones expressed
CD3, CD4, CD45RO, and T cell receptor-a/b, but was negative
for CD8, CD45RA, and the B cell marker CD19, indicating that
BP180-speci®c T lymphocytes from BP patients exhibit a CD4
memory T cell phenotype (data not shown).
The cytokine pro®le of the BP T cells was determined as
followed. T cells were activated by anti-CD3 antibodies in the
presence of phorbol myristate acetate for 30 h. The expression of
IL-2, IL-4, IL-5, IL-6, TGF-b, and IFN-g in these T cells was
analyzed by reverse transcription±PCR using speci®c sets of
cytokine primers as described (Brenner et al, 1989) and commercial
human cytokine enzyme-linked immunosorbent assay kits. As
shown in Fig 5, a representative T cell clone predominantly
expressed IL-2, IL-5, and IFN-g mRNA, and also relatively smaller
Figure 2. A long-term BP patient expresses anti-BP180 antibodies
during the early, but not the later, stages of disease. Serum samples of
patient NE [collection dates 1992 (shortly after disease onset) and 1998 (late
phase of disease)] were assayed by immunoblotting for reactivity to
sec180e. Human sera were used at a dilution of 1:100, and the rabbit anti-
BP180 at a dilution of 1:1000. Lane 1, positive control (rabbit anti-BP180
antibodies); lane 2, negative control (serum from a normal individual); lane
3, serum from NE (1998 bleeding); lane 4, serum from NE (1992 bleeding).
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amounts of IL-4 and IL-6, but was negative for TGF-b mRNA.
Similar results were obtained from other T cell lines and clones
recognizing either NC16A2 or NC16A3. These data were
con®rmed by enzyme-linked immunosorbent assay methods (not
shown). These results indicated that NC16A-speci®c T cells from
BP patients produce a Th1/Th2 mixed cytokine pro®le.
DISCUSSION
The data presented in this paper demonstrate that the NC16A
stretch of the BP180 ectodomain contains epitopes recognized by
both autoantibodies and T cells from the majority of BP patients. T
lymphocytes from the control groups did not respond to the BP180
peptides and T cells from BP patients did not respond to control
epidermal antigens, ®ndings which established the antigen
speci®city and disease association of this T cell response. T
lymphocytes exhibiting a proliferative response to BP180 NC16A
peptides were found only in those BP patients who had detectable
levels of circulating autoantibodies directed against this same
antigen. Of particular interest were the epitope mapping results that
revealed that T cell lines and clones generated from four BP
patients recognize the same narrowly de®ned antigenic sites as those
of the autoantibodies from the corresponding patients. These results
provide evidence that antigenic sites located on the BP180 NC16A
domain may well be involved in triggering the autoimmune
response in BP.
It remains unclear, however, which, if any, of the BP180
epitopes are involved in dermal±epidermal detachment in BP.
Passive transfer mouse model studies have clearly shown that the
pathogenically active antibodies recognize a site on murine BP180
homologous with the human NC16A domain. These ®ndings
formed the basis for our in-depth analysis of the T and B cell
responses directed to the NC16A domain of human BP180.
Nevertheless, it must be kept in mind that BP-associated epitopes
on the BP180 antigen are not solely restricted to NC16A. For
example, BuÈdinger et al (1998) showed that T cells from some BP
patients recognize BP180 fragments outside the NC16A domain,
although these epitopes were not precisely de®ned. In another
study (Perriard et al, 1999), it was shown that autoantibodies from
some BP sera react with sites on the BP180 intracellular domain.
In order to determine whether the NC16A-responsive T cells
belong to the CD4 or CD8 lineage, BP T cells were negatively
selected using antibodies to these surface markers and were assayed
by the cell proliferation protocol. The results of this analysis clearly
demonstrated that the NC16A-speci®c BP T cells are of the CD4-
positive cell lineage, a T cell population known to support B
lymphocytes in the production of antibodies. This conclusion was
further supported by the ®ndings that all NC16A-speci®c T cell
lines and clones derived from four BP patients express the CD4, but
not the CD8, T cell marker.
Of the 12 BP patients tested, four (AP, LH, ES, and NE) did not
exhibit a T cell response to BP180 peptides. Signi®cantly, these
were the same four patients whose sera exhibited no immunor-
eactivity to the BP180 antigen. In at least one of these cases (NE),
the serum sample (from which the T cells and circulating antibodies
were isolated) was obtained from the patient over 6 y after disease
onset. Interestingly, a serum sample that had been collected from
this same patient during the early phase of disease did contain anti-
BP180 autoantibodies, but, due to lack of cell samples, whether T
cells respond to BP180 at that time could not be assessed. Thus,
whereas it appears that anti-BP180 autoantibodies may be crucial in
triggering subepidermal blister formation during the initial stages of
BP, other mechanisms (possibly involving the action of anti-BP230
autoantibodies) may predominate in the later phases of this disease.
Further, in a subset of BP cases (possibly represented by patients
AP, LH and ES) it appears that even the initiatory autoimmune
response may be directed to structural molecules of the dermo±
epidermal junction besides the BP180.
In this study, we also report detailed autoantibody epitope
mapping using an immunoblotting assay. We found that the
NC16A region of BP180 contains the major epitopes recognized
by BP autoantibodies, with NC16A1±3 (aa 492±534) as the
dominant target area. After depletion of reactivity to NC16A1±3,
the BP sera lost their ability to react with sec180e, indicating that,
within the limits of sensitivity of the immunoblotting assay, no
autoantibody-reactive sites on the BP180 ectodomain outside
NC16A1±3 could be uncovered. A similar conclusion was reached
in a previous study by our research group that focused on de®ning
the BP-associated epitopes on the BP180 ectodomain (Zillikens
et al, 1997). Interestingly enough, T cell lines and clones developed
from four BP patients recognized the same peptide stretches within
the NC16A region as those bound by the autoantibodies, indicating
that the BP180 epitopes targeted by autoimmune T and B cells
from BP patients are located in close proximity to one another. In a
similar vein, we have recently shown that T cells and auto-
Figure 3. T cells from BP patients respond to NC16A fusion
proteins. The response of BP T cells to NC16A fusion proteins was
examined using the proliferation assay as described. T cells at a density of
105 per ml were cultured with antigen-pulsed autologous antigen-
presenting cells in a 96-well plate for 7 d. Cells were pulsed with 3H-
thymidine during the last 18 h of incubation and subsequently analyzed for
radioactivity uptake by liquid scintillation counting. Data of a representa-
tive patient, ED, are displayed here. Total T cells (A), CD8-depleted T
cells (B), and CD4-depleted T cells (C).
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antibodies from two HG patients react with the same NC16A
peptide (Lin et al, 1999b). The colocalization of T and B cells
epitopes in the same area of an antigen has been identi®ed in other
autoimmune diseases such as multiple sclerosis (Wucherpfennig et al,
1997) and myasthenia gravis (Atassi and Oshima, 1997). In our
study, however, T cells from patients BM and AN expressing the
anti-BP180 against NC16A1 epitope, failed to proliferate to this
peptide. Currently, it is not clear why this peptide did not stimulate
autoimmune BP T cells. It is possible that the frequency of
NC16A1-reactive T cells is too low to be detectable in these two
patients. These results further indicate the complexity of the BP
autoimmune responses.
It is well established that the antibody isotype produced by a
given B cell is dependent on the type of helper T lymphocytes
that it encounters during activation (Lin and Chen, 1993). For
example, T cells that secrete Th1 cytokines are capable of
stimulating B cells to produce IgG1, whereas Th2 type
cytokines can induce B cells to secrete IgG4 (Armitage et al,
1993). In HG, it was reported that NC16A2-speci®c T cells
secrete a Th1 cytokine pro®le (Lin et al, 1999b). In this study,
using reverse transcription±PCR and speci®c cytokine primers,
we found that all NC16A-speci®c T cell lines and clones
(n = 12) developed from four BP patients (ED, SC, LT, and
BM) produce IL-2, IL-4, IL-5, IL-6, and IFN-g at the mRNA
and the protein level, indicating that these T cells express both
Th1-type and Th2-type cytokines. This conclusion is similar to
that drawn by BuÈdinger et al (1998), who showed that BP180-
speci®c T cells secrete a Th1/Th2 cytokine pro®le. Whether
these cytokines modulate the production of anti-BMZ anti-
bodies in BP patients is currently under investigation.
Previously, Delgado et al (1996) reported that there is a
strong association of HLA-DQB1*0301 with the development
of BP. It remains unclear, however, as to whether the
production of anti-BP180 and/or anti-BP230 autoantibodies is
associated with the expression of this MHC II allele. It was
shown that the T cell response from normal individuals and BP
patients to the BP180 extracellular domain is restricted to the
expression of DQB1*0301 (BuÈdinger et al, 1998). As almost all
BP patients recruited for their study expressed this particular
MHC II allele, this observation re¯ects the autoimmune
reaction in a particular subset of BP patients. Although the
majority of BP patients in our study express HLA-DQB1*0301,
it is not clear whether the expression of this MHC II molecule
is strongly associated with the development of both the humoral
and cellular immune responses against BP180 in these patients.
A preliminary study, however, demonstrated that anti-HLA-DQ
antibodies inhibit the proliferative responses of patient ED T
cells to NC16A3, suggesting that the T cell immune response
to BP180 may be restricted to HLA-DQ (not shown).
In conclusion, the data presented in our study provide
evidence that the NC16A region of the BP180 molecule
harbors epitopes recognized by both autoimmune T lympho-
cytes and autoantibodies from BP patients, suggesting that this
region may modulate the autoimmune reaction in BP. This
information may help us to understand the underlying
autoimmune mechanisms in the development of BP. Now that
the epitopes recognized by BP autoimmune T lymphocytes
have been identi®ed, we can use this information to design
inhibitory peptides or altered peptide ligands to downregulate
the disease-associated T cell response (Sloan-Lancaster et al,
1994; Sloan-Lancaster and Allen, 1996).
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Figure 4. T cell lines and clones developed
from BP patients respond to NC16A fusion
proteins. T cell lines and clones were developed
from BP patients as described. The speci®city of
these T cells to NC16A fragments was examined
using the proliferation assay. Data of representative
T cell lines and clones are shown here. T cell
clone ED10 from patient ED (A), T cell clone
BM78 from patient BM (B), T cell line LT1 from
patient LT (C), and SC1 from patient SC (D).
Figure 5. BP180-speci®c T cells express a Th1/Th2 mixed cytokine
pro®le. The expression of cytokine mRNA in T cell lines or clones
developed from BP patients was examined by reverse transcription±PCR as
described (Brenner et al, 1989). The PCR products were subsequently
fractionated on a 1.5% agarose gel and visualized with ethidium bromide.
The data of a representative T cell clone BM77 are shown here. Lane M,
molecular weight marker; lane 1, IL-2; lane 2, IL-4; lane 3, IL-5; lane 4,
IL-6; lane 5, IFN-g; lane 6, TGF-b; lane 7, b-actin.
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